patients

Social Media Offers Pharma, Physicians Opportunities for Better Interaction with Consumers

In a recent Marketing: Health blog post at MediaPost, Kathy Thorbahn of Razorfish Health, a marketing/advertising/public relations firm focused on health care industries, makes a strong case for the pharmaceutical industry to fully embrace social media in its efforts to give balanced information for consumers to make good health decisions. While several companies are experimenting …

Social Media Offers Pharma, Physicians Opportunities for Better Interaction with Consumers Read More »

Thought Leader Select's Meade Issues Statement on Health Reform

FOR IMMEDIATE RELEASE April 1, 2010 (CHAPEL HILL, NC)—Paul Meade, President of Thought Leader Select, a North Carolina firm dedicated to better engagement and more sophisticated deployment of key opinion leaders for the pharmaceutical industry, issued the following statement regarding the Pharmaceutical Research and Manufacturing Association of America’s (PhRMA) March 21 statement on healthcare reform. …

Thought Leader Select's Meade Issues Statement on Health Reform Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five

Over the past several weeks, we’ve talked about how collaborations among key opinion leaders, clinical investigators and pharmaceutical and biotechnology companies benefit the companies, the KOLs or clinical investigators, and patients. The foundation of these mutually-beneficial collaborations is the objective, methodical approach to understanding KOLs’ and clinical investigators’ skills and experiences. Many methods promise to …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four

Pharmaceutical & Biotechnology Companies Provide Early Knowledge-building Opportunities for KOLs and Clinical Investigators Understanding the value that key opinion leaders provide pharmaceutical and biotechnology companies is clear, but how do companies benefit thought leaders and clinical investigators? By definition, KOLs are physicians, scientists and academics who devote time to studying and advancing their craft. Often, …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three

Key Opinion Leaders Help to Foster Robust, Viable Pharmaceutical and Biotechnology Pipelines Imagine a world where pharmaceutical and biotechnology companies developed therapies without input from KOLs at various stages of product discovery and development. The results would be far fewer treatments available, greater risks for unwanted side effects and potentially, a larger number of unnecessary …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Three Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two

KOLs Provide the “Voice of the Patient” for Life-changing Discoveries According to the Pharmaceutical Research and Manufacturers of America (PhRMA—(http://www.phrma.org/), “Only one of every 10,000 potential medicines investigated by America’s research-based pharmaceutical companies makes it through the research and development pipeline and is approved for patient use by the United States Food and Drug Administration.” …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part Two Read More »

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One

Now more than ever, pharmaceutical companies’ relationships with physician thought leaders, also known as key opinion leaders (KOLs), are under intense scrutiny. Industry ethicists and watchdogs alike have speculated on the objectivity of medical education presentations and other aspects of KOL involvement during the marketing of new drug therapies. However, the truth is that physician …

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma and Patients—Part One Read More »